Tuesday, July 17, 2012

Simvastatin 80 mg FDA report

*I have attached a FDA report from 1 year ago . It basically recommends that doctors not increase the dose of Zocor ( simvastatin ) to 80 mg/d because of increased risk of simvastatin - related muscle damage( myopathy).

*Doubling the dose of zocor from 40 to 80 mg/day more than doubles the risk of myopathy while only lowering the LDL cholesterol by about another 6 to 7 %.

*Zocor is one of the most commonly ordered statins because it is safe , effective and inexpensive when taking 20 to 40 mg/d.  If higher doses are needed, consider switching to one of the newer more potent Statins , such as lipitor( atrovastatin ) or Crestor ( rosuvastatin ) , that provide better  initial LDL cholesterol reduction and lower risk of myopathy .

*See my Rule of 7  discussion in my June 11,2012 post. Basically statins provide their greatest reduction in LDL , any where from 27 to 40 % in most people , with the initial dose and subsequent doubling the statin doses provides only about another 6 to 7 % reduction in LDL.

Have Fun , Be Smart , Lipitor is now available as a generic
David Calder,MD

FDA: Limit Use of 80 mg Simvastatin
The Food and Drug Administration is recommending that the use of drugs containing 80 mg of simvastatin—the highest approved dose of the popular cholesterol-lowering statin—be sharply curtailed because of the risk of muscle injury.
FDA says this dose should only be used by patients who have been taking it for 12 months or longer without ill effect.
“Our overall goal is to get doctors to not start patients on 80 mg of simvastatin,” says Eric Colman, M.D., deputy director of FDA’s Division of Metabolism and Endocrinology Products.
And if health care professionals find that patients now taking 40 mg of simvastatin aren’t meeting their LDL cholesterol goal, FDA is advising them to choose a different statin rather than raising the simvastatin dose to 80 mg, says Amy Egan, M.D., deputy director for safety in the FDA division.
All statins, despite their proven benefit in lowering the risk of heart attacks and strokes, carry some risk of an injury called myopathy, characterized by unexplained muscle weakness or pain. 
But the risk is greater for patients who take the 80 mg doses of simvastatin, especially in the first year of treatment. Colman says the muscle damage is often caused by interactions with other medications. And some people are genetically predisposed towards simvastatin-related myopathy, he says.
Last year, an estimated 2.1 million people were prescribed a medication containing 80 mg of simvastatin, says Egan. “It is the most potent statin available in generic form and is relatively inexpensive,” she notes.
The statin is sold under the brand name Zocor and as a single-ingredient generic drug. It is also sold in combination with ezetimibe as Vytorin, and niacin as Simcor.
FDA has revised the drug labels for simvastatin and Vytorin to include the new restrictions for the 80 mg dose, says Egan. The labels of simvastatin, Vytorin and Simcor have all been changed to include dosing recommendations when these drugs are used with medicines that can increase the level of simvastatin in the body, thus increasing the risk of myopathy.
Like all statins, simvastatin is used to lower the amount of low-density lipoprotein (LDL) cholesterol—known as “bad cholesterol”—in the blood. And the 80 mg dose of simvastatin has been shown to lower LDL cholesterol by an additional 6% over the 40 mg dose.
But myopathy can be debilitating. Moreover, a rare form of myopathy, called rhabdomyolysis, can lead to kidney failure and death.
Colman says one thing FDA does not want patients to do is stop taking their statins without consulting their doctor. “The benefits of the treatment far outweigh the risks,” he says, calling occurrences of rhabdomyolysis “extremely rare.”
But Egan says you should contact your health care professional if you have:
  • Muscle pain, tenderness or weakness
  • Dark or red-colored urine
  • Unexplained fatigue
The FDA recommendation was prompted by a comprehensive review of clinical trial data and data from the agency’s Adverse Event Reporting System, one of FDA's most important tools for tracking the safety of drugs once they are on the market.
Egan explained that FDA did not want to risk the health of patients who have been successfully treated with the medication for a year or more by pulling it off the market. During the next year, the agency will monitor prescription data to determine if the labeling changes are successful in limiting the use of 80 mg simvastatin.
This article appears on FDA's Consumer Updates page, which features the latest on all FDA-regulated products.
June 8, 2011

No comments:

Post a Comment

Your comments and questions are appreciated. David Calder,MD